Skip to content
value.today
Exagen Inc. logo

Exagen Inc.

XGN
$218 Mmarket cap on Oct 16, 2026+561.8% since Jan 2024
1M
+1.8%
Compare
World rank
#15,928
Revenue
$67 M
For year ending December-2025
Net income
$-20 M
-30.0% margin
SEC filing
Employees
220
As of December 31, 2025
SEC filing

Exagen Inc. in brief

Exagen Inc. is a listed company in the Diagnostics and Research industry, based in Vista, California, USA. It was founded in 2002. Its market value was $218 M on 16 October 2026, which makes it the 15,928th largest listed company in the world and the 3,098th largest in the USA on this site. In the year to December 2025 it had sales of $67 M and a net loss of $20 M. It employs about 220 people and John Aballi is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol XGN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Exagen Inc.

We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE® brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other specialists, and the patients they serve.

From the company's annual report filed with the US SEC: read the report

Exagen Inc. timeline

6 events, 2002–2025
  1. 2002
  2. 🏁
    · approximate
    Founded
  3. 2003
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2014
  6. •
    Legal Entity Identifier issued
    LEI 549300JV2CYDOME5OO17 registered.
  7. 2017
  8. ✎
    Renamed Exagen Inc.
    Formerly Exagen Diagnostics Inc.
  9. 2019
  10. 🔔
    · approximate
    Initial public offering on Nasdaq as XGN
  11. 2025
  12. 💰
    Record revenue of $67 million
    FY2025, the highest of the 8 years on record.

Events of Exagen Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$88 M$176 M$263 M$351 M2020202120222023202420252026

World rank over time

▼ down 2,591 places since 2020
2020-01-01: #13379#13,37920202021-01-01: #16211#16,21120212022-01-07: #19835#19,83520222022-12-25: #26220#26,22020222023-07-30: #26220#26,22020232024-01-05: #26843#26,84320242026-03-08: #10387#10,38720262026-08-01: #16031#16,03120262026-09-21: #16083#16,08320262026-10-16: #15970#15,9702026

Rank in USA: #2,829 (Jan 2020) · #3,363 (Jan 2021) · #3,979 (Jan 2022) · #4,934 (Dec 2022) · #4,850 (Jul 2023) · #4,232 (Jan 2024) · #2,026 (Mar 2026) · #3,208 (Aug 2026) · #3,096 (Sep 2026) · #3,102 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
3.0×
Price / book
12.5×
Free cash flow yield
-6.5%
Net margin (TTM)
-25.1%
Operating margin
-21.1%
Return on equity
-104.2%
Liabilities / assets
69.9%
Net debt
$-9M
Revenue growth
+19.7%
R&D / revenue
9.4%
Revenue per employee
$303 K
Profit per employee
$-91 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $32M, net income $-8M$32MFY18Fiscal year ending Dec 2019: revenue $40M, net income $-12M$40MFY19Fiscal year ending Dec 2020: revenue $42M, net income $-17M$42MFY20Fiscal year ending Dec 2021: revenue $48M, net income $-27M$48MFY21Fiscal year ending Dec 2022: revenue $46M, net income $-47M$46MFY22Fiscal year ending Dec 2023: revenue $53M, net income $-24M$53MFY23Fiscal year ending Dec 2024: revenue $56M, net income $-15M$56MFY24Fiscal year ending Dec 2025: revenue $67M, net income $-20M$67MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$67M+19.7%$-14M$-20M-30.0%
Dec 2024$56M+5.9%$-14M$-15M-27.2%
Dec 2023$53M+15.3%$-23M$-24M-45.1%
Dec 2022$46M-5.7%$-46M$-47M-104.0%
Dec 2021$48M+15.1%$-24M$-27M-55.6%
Dec 2020$42M+3.9%$-15M$-17M-39.8%
Dec 2019$40M+24.5%$-9M$-12M-29.8%
Dec 2018$32M—$-5M$-8M-24.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-14M$1M$-14M$-0.93—
Dec 2024$-13M$1M$-14M$-0.83—
Dec 2023$-14M$1M$-15M$-1.34—
Dec 2022$-32M$4M$-36M$-2.77—
Dec 2021$-20M$2M$-23M$-1.68—
Dec 2020$-14M$0M$-15M$-1.32—
Dec 2019$-10M$0M$-10M$-8.46—
Dec 2018$-9M$0M$-10M$-293.34—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$72M
Net income, trailing 12 months
$-18M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $14M, net income $-4M$14MDec ’24Three months to Mar 2025: revenue $16M, net income $-4M$16MMar ’25Three months to Jun 2025: revenue $17M, net income $-4M$17MJun ’25Three months to Sep 2025: revenue $17M, net income $-7M$17MSep ’25Three months to Dec 2025 (from the annual report): revenue $17M, net income $-5M$17MDec ’25Three months to Mar 2026: revenue $17M, net income $-4M$17MMar ’26Three months to Jun 2026: revenue $20M, net income $-3M$20MJun ’26Three months to Sep 2026: revenue $18M, net income $-6M$18MSep ’26

Latest quarter to Sep 2026: revenue $18M (+6.8% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Exagen Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$67 M
Operating income
$-14 M
Net income
$-20 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$58 M
Total liabilities
$41 M
Total equity
$17 M

As of December-2025

Top 78 institutional investors in Exagen Inc.#

As of Sep 30, 2026
78 institutions held 10.4 M shares (about 40.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 21.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Exagen Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Parkman Healthcare Partners LLC926,548New3.63%$8 MNov 16, 2026
2Wexford Capital LP759,835-33,020 (-4.16%)2.98%$6 MNov 13, 2026
3Nano Cap New Millennium Growth Fund L P700,000+25,000 (+3.70%)2.74%$6 MNov 13, 2026
4Vanguard Capital Management LLC623,907+11,075 (+1.81%)2.45%$5 MNov 13, 2026
5Mink Brook Asset Management LLC531,673+55,729 (+11.71%)2.08%$4 MNov 13, 2026
6First Eagle Investment Management, LLC516,098-97,832 (-15.94%)2.02%$4 MNov 10, 2026
7Silvercrest Asset Management Group LLC469,457-45,304 (-8.80%)1.84%$4 MNov 16, 2026
8Marshall Wace, LLP392,789+86,086 (+28.07%)1.54%$3 MNov 13, 2026
9FourWorld Capital Management LLC352,543-243,985 (-40.90%)1.38%$3 MNov 16, 2026
10Acadian Asset Management LLC311,482+1,398 (+0.45%)1.22%$3 MNov 9, 2026
11Schonfeld Strategic Advisors LLC310,091New1.22%$3 MNov 16, 2026
12Flputnam Investment Management Co299,828+11,018 (+3.81%)1.18%$2 MNov 13, 2026
13Kennedy Capital Management LLC295,832-189,216 (-39.01%)1.16%$2 MNov 13, 2026
14Citadel Advisors LLC273,804+259,411 (+1802.34%)1.07%$2 MNov 16, 2026
15BlackRock, Inc.255,675+113,050 (+79.26%)1.00%$2 MNov 13, 2026
16Man Group plc214,760+47,468 (+28.37%)0.84%$2 MNov 16, 2026
17Gsa Capital Partners LLP200,600-14,121 (-6.58%)0.79%$2 MNov 16, 2026
18Jane Street Group, LLC193,744-128,758 (-39.92%)0.76%$2 MNov 12, 2026
19Geode Capital Management, LLC186,642+988 (+0.53%)0.73%$2 MNov 6, 2026
20Two Sigma Investments, LP175,387+115,395 (+192.35%)0.69%$1 MNov 16, 2026
21Susquehanna International Group, LLP151,661New0.59%$1 MNov 16, 2026
22Squarepoint Ops LLC148,608+39,615 (+36.35%)0.58%$1 MNov 9, 2026
23XTX Topco Ltd139,961+28,013 (+25.02%)0.55%$1 MNov 16, 2026
24Millennium Management LLC127,817New0.50%$1 MNov 16, 2026
25Perceptive Advisors LLC114,8930 (0.00%)0.45%$1 MNov 16, 2026
Show all 78: investors 26 to 78
Institutional investors 26 to 78 in Exagen Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26D. E. Shaw & Co., Inc.106,268+56,556 (+113.77%)0.42%$1 MNov 16, 2026
27Vanguard Fiduciary Trust Co101,846-6,803 (-6.26%)0.40%$1 MNov 13, 2026
28Walleye Capital LLC96,196New0.38%$1 MNov 13, 2026
29GWN Securities Inc.87,310+9,276 (+11.89%)0.34%$1 MNov 12, 2026
30Trexquant Investment LP86,067New0.34%$1 MNov 16, 2026
31Jump Financial, LLC81,714+69,989 (+596.92%)0.32%$1 MNov 13, 2026
32State Street Corp79,356+8,100 (+11.37%)0.31%$1 MNov 12, 2026
33BNP Paribas Financial Markets72,059+72,030 (+248379.31%)0.28%$1 MNov 12, 2026
34SEI Investments Co65,091-43,914 (-40.29%)0.26%$1 MNov 10, 2026
35Goldman Sachs Group Inc59,956+7,874 (+15.12%)0.23%$0 MNov 16, 2026
36Qube Research & Technologies Ltd59,591New0.23%$0 MNov 13, 2026
37Renaissance Technologies LLC59,382+19,782 (+49.95%)0.23%$0 MNov 12, 2026
38Morgan Stanley55,312+48,974 (+772.70%)0.22%$0 MNov 13, 2026
39Perkins Capital Management Inc55,296-1,500 (-2.64%)0.22%$0 MNov 2, 2026
40Jpmorgan Chase & Co53,825+53,697 (+41950.78%)0.21%$0 MNov 12, 2026
41Russell Investments Group, Ltd.51,458New0.20%$0 MNov 6, 2026
42HRT Financial LP48,577+32,480 (+201.78%)0.19%$0 MNov 13, 2026
43HSBC Holdings PLC46,703New0.18%$0 MNov 16, 2026
44Quadrature Capital Ltd46,528New0.18%$0 MNov 13, 2026
45Northern Trust Corp39,5130 (0.00%)0.15%$0 MNov 16, 2026
46Occudo Quantitative Strategies LP38,970+18,338 (+88.88%)0.15%$0 MNov 16, 2026
47Bridgeway Capital Management, LLC29,596-406 (-1.35%)0.12%$0 MNov 16, 2026
48Globeflex Capital L P24,619New0.10%$0 MNov 16, 2026
49Empowered Funds, LLC24,396New0.10%$0 MNov 13, 2026
50Algert Global LLC23,950New0.09%$0 MNov 17, 2026
51Brevan Howard Capital Management LP21,777New0.09%$0 MNov 16, 2026
52R Squared Ltd21,649-4,424 (-16.97%)0.08%$0 MNov 6, 2026
53Bank of New York Mellon Corp20,9380 (0.00%)0.08%$0 MNov 5, 2026
54Arax Advisory Partners20,9180 (0.00%)0.08%$0 MNov 12, 2026
55Engineers Gate Manager LP19,932-17,068 (-46.13%)0.08%$0 MNov 16, 2026
56Invesco Ltd.16,342-4,791 (-22.67%)0.06%$0 MNov 12, 2026
57Point72 Asset Management, L.P.16,267New0.06%$0 MNov 16, 2026
58Arrowstreet Capital, Limited Partnership14,550New0.06%$0 MNov 13, 2026
59PDT Partners, LLC14,000New0.05%$0 MNov 16, 2026
60Jain Global LLC12,263New0.05%$0 MNov 16, 2026
61Bank Of America Corp /de/11,707New0.05%$0 MNov 16, 2026
62Calamos Advisors LLC11,518New0.05%$0 MNov 2, 2026
63Penbrook Management LLC11,300New0.04%$0 MOct 16, 2026
64Corient Private Wealth LP11,0930 (0.00%)0.04%$0 MNov 16, 2026
65Barclays PLC9,627+4,134 (+75.26%)0.04%$0 MNov 6, 2026
66Vanguard Global Advisers, LLC8,408+4,267 (+103.04%)0.03%$0 MNov 13, 2026
67UBS Group AG6,553+2,494 (+61.44%)0.03%$0 MNov 10, 2026
68Citigroup Inc5,392New0.02%$0 MNov 4, 2026
69Wells Fargo & Company/mn2,3870 (0.00%)0.01%$0 MNov 16, 2026
70Osaic Holdings, Inc.1,1000 (0.00%)0.00%$0 MNov 12, 2026
71Geneos Wealth Management Inc.1,0000 (0.00%)0.00%$0 MNov 9, 2026
72Farther Finance Advisors, LLC990New0.00%$0 MOct 8, 2026
73Rothschild Investment LLC600New0.00%$0 MNov 10, 2026
74Group One Trading LLC586New0.00%$0 MNov 10, 2026
75Jones Financial Companies Lllp2000 (0.00%)0.00%$0 MNov 13, 2026
76Latitude Advisors, LLC100New0.00%$0 MOct 27, 2026
77Tower Research Capital LLC (TRC)98-2,870 (-96.70%)0.00%$0 MNov 16, 2026
78Caitong International Asset Management Co., Ltd8-40 (-83.33%)0.00%$0 MOct 29, 2026

Mutual funds holding Exagen Inc.#

24 funds hold shares worth $6 M (about 3.7% of the company). Since their previous reports 6 added shares and 8 sold, buying $1 M net.
Mutual funds holding Exagen Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 First Eagle Small Cap Opportunity FundFirst Eagle Investment Management, LLC435,574$2 M1.2%0.07%+296%Jul 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.414,852$2 M1.2%<0.01%−19%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.179,415$1 M0.50%<0.01%+14%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC82,372$0 M0.23%<0.01%−0.8%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors55,958$0 M0.16%0.02%+41%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC25,808$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC24,802$0 M0.07%0.08%−34%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC22,903$0 M0.06%<0.01%+11%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP25,070$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC11,992$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.10,707$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.7,858$0 M0.02%<0.01%−9.3%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP8,014$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC3,782$0 M0.01%<0.01%+34%Jun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP3,498$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP3,419$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP3,129$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP3,009$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors2,762$0 M<0.01%<0.01%−24%Jun 30, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP1,831$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,605$0 M<0.01%<0.01%−8.7%Jul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC1,000$0 M<0.01%<0.01%−47%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC811$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP755$0 M<0.01%<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 24 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Exagen Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$569 K
4 purchases, 1 insider
Sold, 12 months
$1.3 M
8 sales, 3 insiders
Net, 12 months
-$769 K
open market only
Insiders on file
19
since
$464 K-$1.2 M$0Feb 2024: bought $0 (0 trades), sold $13 K (1 trades)Feb 24Mar 2024: bought $0 (0 trades), sold $24 K (2 trades)May 2024: bought $78 K (1 trades), sold $0 (0 trades)MayNov 2024: bought $135 K (2 trades), sold $660 K (1 trades)Mar 2025: bought $0 (0 trades), sold $1.2 M (1 trades)MarSep 2025: bought $0 (0 trades), sold $200 K (1 trades)Oct 2025: bought $0 (0 trades), sold $376 K (1 trades)OctFeb 2026: bought $0 (0 trades), sold $47 K (2 trades)Mar 2026: bought $0 (0 trades), sold $57 K (1 trades)MarSep 2026: bought $0 (0 trades), sold $149 K (1 trades)Oct 2026: bought $104 K (1 trades), sold $270 K (1 trades)OctNov 2026: bought $464 K (3 trades), sold $815 K (3 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Exagen Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jorey Chernett10% ownerSell-58,068$4.080$237 K2.53 MForm 4
filed Jorey Chernett10% ownerSell-109,436$4.650$509 K2.59 MForm 4
filed Jorey Chernett10% ownerBuy+71,315$5.230$373 K2.70 MForm 4
filed Jorey Chernett10% ownerBuy+7,085$5.260$37 K2.63 MForm 4
filed Jorey Chernett10% ownerBuy+8,500$6.350$54 K2.62 MForm 4
filed Jorey Chernett10% ownerSell-11,265$6.140$69 K2.61 MForm 4
filed Jorey Chernett10% ownerBuy+14,000$7.460$104 K2.62 MForm 4
filed John AballiPresident and CEO, DirectorSell-34,294$7.867$270 K805,540Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Exagen Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
727,455
3.2% of shares · 1.98 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-183.62 reverse split

Fails to deliver

  • : 5,600 shares at $8.56
  • : 951 shares at $8.41
  • : 67 shares at $7.58
  • : 5,000 shares at $7.92
  • : 1,103 shares at $7.43

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Exagen Inc. scorecard#

Passes 8 of the 22 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 16, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median12.5×Price to book 12.5× against Diagnostics and Research's median of 3.7×.
    • ✓Price to sales below its peers' median3.0×Price to sales 3.0× against Diagnostics and Research's median of 4.5×.
    • ✗Free cash flow yield above 5%-6.5%Free cash flow is -6.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year19.7%Revenue up 19.7% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years13.5%13.5% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median13.5%13.5% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year-0.93 vs -0.83Diluted EPS -0.93 in fiscal 2025 against -0.83 the year before (report's currency).
    • ✗Net income higher than five years earlier-$20 M-$20 M in fiscal 2025 against -$17 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-21.1%-21.1% against Diagnostics and Research's median of -2.4% (66 companies).
    • ✗Return on equity above 15%-147.8%-147.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-21.1%-21.1% in fiscal 2025 against -101.1% in 2022.
  • Financial health2 of 5
    • ✓Short-term assets cover short-term liabilities3.5×Current ratio 3.45 at the end of fiscal 2025.
    • ✗Debt below equity1.3×Debt to equity 1.31 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $9 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-3.29Z-score -3.29 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year18.4%Diluted shares up 18.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Exagen Inc.'s statements, beside the median of Diagnostics and Research.

Exagen Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-21.1%-2.4%
Net margin-30.0%-3.6%
Return on equity-147.8%-5.4%
Revenue growth, 3 years a year13.5%3.6%
Revenue growth19.7%6.6%
Debt to equity1.31×0.57×

3of 9on the Piotroski tests of financial strength

  • Net loss of $20 million, the 8th loss-making year in a row.
  • Free cash flow was negative: -$14 million.
  • The share count rose 18.4% in the year.
  • Revenue has grown 3 years in a row.

Exagen Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Exagen Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue6756534648424032
Cost of revenue2823232421171915
Gross profit393329—————
Research and development6.35.44.99.97.23.62.22.1
Selling, general and administrative4741475245372920
Total costs and expenses534752r9272575037
Operating income−14−14−23−46−24−15−9.3−4.9
Interest and finance income0.30.81.5—————
Interest expense and finance costs4.32.22.32.42.62.63.52.9
Other non-operating income (expense)————0.01.00.50.1
Income tax0.10.00.0−0.30.2−0.10.00.1
Net income attributable to shareholders−20−15−24−47−27−17−12−8.0
Earnings per share, basic-0.93-0.83-1.34-2.77-1.68-1.32-8.46-293.34
Earnings per share, diluted-0.93-0.83-1.34-2.77-1.68-1.32-8.46-293.34
Shares, weighted average (basic)221818171613——
Shares, weighted average (diluted)2218181716133.60.1
Balance sheet
Cash and cash equivalents3222366299577213
Receivables117.86.6r6.1r9.7r8.95.76.0
Other current assets3.35.72.91.81.11.21.41.2
Current assets49364873113718121
Property, plant and equipment6.95.35.28.24.82.11.41.6
Right-of-use (leased) assets1.42.43.34.90———
Goodwill———05.55.55.55.5
Total assets58455786123788829
Accounts payable4.24.13.13.02.53.01.51.3
Debt due within a year0.60.40.30.20———
Current liabilities1414129.69.38.85.99.0
Long-term debt2220192927272625
Lease liabilities (non-current)0.41.72.84.50———
Total liabilities4135344439373336
Retained earnings−314−294−279−256−208−181−165−153
Shareholders' equity179.52342854256−112
Total liabilities and equity58455786123788829
Shares outstanding231817171613130.1
Cash-flow statement
Depreciation and amortization2.11.72.21.60.90.50.60.6
Share-based compensation2.21.83.64.74.72.70.60.1
Cash from operating activities−14−13−14−32−20−14−9.7−9.3
Capital expenditure−0.6−0.5−0.8−4.3−2.4−0.5−0.4−0.2
Cash from investing activities−0.6−0.5−0.8−4.3−2.4−0.5−0.1−0.2
Debt issued——————05.0
Debt repaid—0−100————
Shares issued3.40—0690——
Cash from financing activities24−0.7−11−0.565−0.16911
Change in cash10−14−26−3742−15591.9
Report10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Exagen Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable$67 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Exagen Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.4 M
John Aballi
Other top executives, average
$746 K
the CEO earned 1.9× this
$100 invested is now
$253
Exagen Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025John Aballi$1.4 M$2.9 M$746 K$253
2024John Aballi$1.2 M$2.0 M$906 K$168
2023John Aballi$932 K$775 K$985 K$82

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Exagen Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 5 · Material agreement 2 · New debt 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 14

Exagen Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K/A
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

11 private funding rounds before listing

Private share sales · funding history

Private share sales of Exagen Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2019$7 MNo. 11$2 to $10 million4equitySEC
May 2017$4 MNo. 10$2 to $10 million4equitySEC
Jan 2016$17 MNo. 9$10 to $50 million13equitySEC
Oct 2015$3 MNo. 8$2 to $10 million4debt, optionsSEC
Oct 2013$5 MNo. 7$2 to $10 million11equitySEC
Sep 2012$5 MNo. 6$2 to $10 million7equitySEC
Dec 2011$12 MNo. 5$10 to $50 million9equitySEC
Sep 2011$5 MNo. 4$2 to $10 million8equity, debtSEC
Jun 2011$5 MNo. 3$2 to $10 million8equity, optionsSEC
Oct 2010$5 MNo. 2$2 to $10 million17equity, debt, optionsSEC
May 2009$1 MNo. 1Under $2 million15equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Exagen Inc.#

$30 K spent on lobbying the US Congress and federal agencies in 2022, most often on medical/disease research/clinical labs.

Lobbying, 2022
$30 K
#1,320 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—
  • Medical/Disease Research/Clinical Labs3 reports

Lobbying firms hired in 2022

The Raben Group $30 K

Exagen Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$30 K—3
2021$20 K—2

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Exagen Inc”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Layoffs at Exagen Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
42
2022–2022
Latest
42 people
2022-12-05
Exagen Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2022···········4242
Exagen Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
42 peopleRestructuring planSEC 8-K“The Company will reduce its current workforce by 42 employees (the “Reduction in Force”).”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Exagen Inc. compares in Diagnostics and Research

  • Market cap$218 M · higher than 32% of 110
  • Revenue$67 M · higher than 30% of 123
  • Net margin-25.1% · higher than 25% of 112
  • Revenue growth19.7% · higher than 75% of 89
  • Price / sales3.0× · lower than 54% of 85
  • Price / book12.5× · lower than 16% of 84
  • FCF yield-6.5% · higher than 34% of 66

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Exagen Inc.🇺🇸$218 M—-25.1%+19.7%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 16, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, Wikimedia Commons, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Exagen Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Exagen Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Exagen Inc.? Suggest a correction